Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Censoring Survival Data01:09

Censoring Survival Data

80
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
80
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

122
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
122
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

129
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
129
Test for Homogeneity01:23

Test for Homogeneity

2.0K
The goodness–of–fit test can be used to decide whether a population fits a given distribution, but it will not suffice to decide whether two populations follow the same unknown distribution. A different test, called the test for homogeneity, can be used to conclude whether two populations have the same distribution. To calculate the test statistic for a test for homogeneity, follow the same procedure as with the test of independence. The hypotheses for the test for homogeneity can...
2.0K
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

194
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
194

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cancer risk with methotrexate-TNF antagonist combination therapy compared to TNF-antagonist monotherapy in IBD.

Inflammatory bowel diseases·2026
Same author

Toward Artificial Intelligence-driven Clinical Decision Support Tools in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same author

Statistics and AI - A Fireside Conversation.

Harvard data science review·2026
Same author

Design and Analysis of Randomized Clinical Trials With Average Hazard: Practical Guidance and Tools for Implementation.

Statistics in medicine·2026
Same author

Predicting the timing of first sustained cognitive worsening in Alzheimer's disease using real-world clinical data and machine learning.

medRxiv : the preprint server for health sciences·2026
Same author

Nonparametric estimation of the total treatment effect with multiple outcomes in the presence of terminal events.

Biometrics·2026

相关实验视频

Updated: Jun 25, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

评估使用受审查数据的代孕异质性.

Layla Parast1, Lu Tian2, Tianxi Cai3

  • 1Department of Statistics and Data Sciences, The University of Texas at Austin, Austin, Texas.

Statistics in medicine
|May 30, 2024
PubMed
概括

这项研究引入了一种新的统计方法,用于评估替代标记物是否具有替代标记物.

科学领域:

  • 生物统计学 生物统计学
  • 临床试验 临床试验
  • 流行病学 流行病学

背景情况:

  • 在临床研究中评估代孕标记是复杂的.
  • 现有的统计方法往往无法解释代用标记器实用性的异质性.
  • 在长期研究中常见的受审查数据,对当前的代孕评估方法构成了挑战.

研究的目的:

  • 开发一种强大的非参数方法来评估替代标记器实用性的异质性.
  • 创建一个测试程序来评估这种异质性在受审查的时间到事件数据.
  • 使用这种新方法,研究血糖控制,糖尿病和性激素之间的关系.

主要方法:

  • 开发了一种新的非参数统计方法,用于评估替代标记器实用性的异质性.
  • 提出并评估了一种测试程序,以检测被审查的时间到事件结果中的异质性.
  • 利用模拟研究来检查拟议方法的有限样本性能.

主要成果:

  • 开发的非参数方法有效地评估了替代标记器实用性的异质性.
  • 拟议的测试程序可以在单个或多个时间点正式测试异质性.
  • 模拟证明了估计和测试程序的可靠性.
关键词:
生物标志物生物标志物没有参数的非参数.幸存率 幸存率 生存率治疗效果治疗效果的治疗效果

更多相关视频

Mouse Round Spermatid Injection
08:41

Mouse Round Spermatid Injection

Published on: January 26, 2024

714
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.6K

相关实验视频

Last Updated: Jun 25, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
Mouse Round Spermatid Injection
08:41

Mouse Round Spermatid Injection

Published on: January 26, 2024

714
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.6K

结论:

  • 这种新方法提供了一种强大的方法来评估与受审查数据的替代标记器实用性的异质性.
  • 这种方法对于了解代孕标记物的表现如何因患者特征而有所不同是有价值的.
  • 该方法在糖尿病预防计划研究中成功应用于分析代孕标志物关系.